Beasley, CM Jr, Ball, SG, Nilsson, ME, Polzer, J, Tauscher-Wisniewski, S, Plewes, J and Acharya, N (2007) Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. Journal of Clinical Psychopharmacology 27, 682–686.
Carney, CE, Segal, ZV, Edinger, JD and Krystal, AD (2007) A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. Journal of Clinical Psychiatry 68, 254–260.
Claassen, CA, Trivedi, MH, Rush, AJ, Husain, MM, Zisook, S, Young, E, Leuchter, A, Wisniewski, SR, Balasubramani, GK and Alpert, J (2007) Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. Journal of Affective Disorders 97, 77–84.
Conradi, HJ, Ormel, J and de Jonge, P (2011) Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychological Medicine 41, 1165–1174.
Craighead, WE, Johnson, BJ, Carey, S and Dunlop, BW (2015) Psychosocial treatments for major depressive disorder. In Nathan, PE and Gorman, JM (Eds), Treatments That Work, 4th Edn. New York: Oxford University Press, pp. 381–408.
Dunlop, BW (2016) Evidence-based applications of combination psychotherapy and pharmacotherapy for depression. Focus 14, 156–173.
Dunlop, BW and Mayberg, HS (2014) Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues in Clinical Neuroscience 16, 479–490.
Dunlop, BW, Binder, EB, Cubells, JF, Goodman, MM, Kelley, ME, Kinkead, B, Kutner, M, Nemeroff, CB, Dewport, DJ, Owens, MJ, Pace, TW, Ritchie, JC, Rivera, VA, Westen, D, Craighead, WE and Mayberg, HS (2012) Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials 13, 106.
Dunlop, BW, Kelley, ME, Aponte-Rivera, V, Mletzko-Crowe, T, Kinkead, B, Ritchie, JC, Nemeroff, CB, Craighead, WE and Mayberg, HS (2017) Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. American Journal of Psychiatry 6, 546–556.
Dunlop, BW, Cole, SP, Nemeroff, CB, Mayberg, HS and Craighead, WE (2018) Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder. Journal of Affective Disorders 229, 111–119.
Fournier, JC, DeRubeis, RJ, Hollon, SD, Gallop, R, Shelton, RC and Amsterdam, JD (2013) Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behaviour Research and Therapy 51, 392–398.
Frank, E, Prien, RF, Jarrett, RB, Keller, MB, Kupfer, DJ, Lavori, PW, Rush, AJ and Weissman, MM (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Archives of General Psychiatry 48, 851–855.
Fried, EI and Nesse, RM (2014) The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS ONE 9, e90311.
Gibbons, RD, Hur, K, Brown, CH, Davis, JM and Mann, JJ (2012) Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Archives of General Psychiatry 69, 572–579.
Greenberg, PE, Fournier, AA, Sisitsky, T, Pike, CT and Kessler, RC (2015) The economic burden of adults with major depressive disorder in the United States (2005 and 2010). Journal of Clinical Psychiatry 76, 155–162.
Hamilton, M (1967) Development of a rating scale for primary depressive illness. British Journal of Clinical Psychology 6, 78–96.
Iovieno, N, van Nieuwenhuizen, A, Clain, A, Baer, L and Nierenberg, AA (2011) Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depression and Anxiety 28, 137–144.
Judd, LL, Paulus, MP, Wells, KB and Rapaport, MH (1996) Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. American Journal of Psychiatry 153, 1411–1417.
Kennedy, JC, Dunlop, BW, Craighead, LW, Nemeroff, CB, Mayberg, HS and Craighead, WE (2018) Follow-up of monotherapy remitters in the PReDICT study: maintenance treatment outcomes and clinical predictors of recurrence. Journal of Consulting and Clinical Psychology 86, 189–199.
Madhoo, M and Levine, SZ (2015) Initial severity effects on residual symptoms in response and remission. Journal of Clinical Psychopharmacology 35, 450–453.
Manber, R, Rush, AJ, Thase, ME, Amow, B, Klein, D, Trivedi, MH, Korenstein, SG, Markowitz, JC, Dunner, DL, Munsaka, M, Borian, FE and Keller, MB (2003) The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Sleep 26, 130–136.
McClintock, SM, Husain, MM, Wisniewski, SR, Nierenberg, AA, Stewart, JW, Trivedi, MH, Cook, I, Morris, D, Warden, D and Rush, AJ (2011) Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. Journal of Clinical Psychopharmacology 31, 180–186.
Montgomery, SA and Åsberg, M (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382–389.
Müller-Oerlinghausen, B, Müser-Causemann, B and Volk, J (1992) Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. Journal of Affective Disorders 25, 261–269.
Nierenberg, AA, Keefe, BR, Leslie, VC, Alpert, JE, Pava, JA, Worthington, JJ, Rosenbaum, JF and Fava, M (1999) Residual symptoms in depressed patients who respond acutely to fluoxetine. Journal of Clinical Psychiatry 60, 221–225.
Nierenberg, AA, Husain, MM, Trivedi, MH, Fava, M, Warden, D, Wisniewski, SR, Miyahara, S and Rush, AJ (2010) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychological Medicine 40, 41–50.
Paykel, ES, Ramana, R, Cooper, Z, Hayhurst, H, Kerr, J and Barocka, A (1995) Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine 25, 1171–1180.
Pratt, LA and Brody, DJ (2014) Depression in the U.S. household population, 2009–2012. NHCS Data Brief 172, 1–8.
Romera, I, Perez, V, Quail, D, Berggren, L, Lenox-Smith, A and Gilaberte, I (2014) Individual residual symptoms and functional impairment in patients with depression. Psychiatry Research 220, 258–262.
Sharma, T, Guski, LS, Freund, N and Gotzsche, PC (2016) Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. The British Medical Journal 352, i65.
Szanto, K, Mulsant, BH, Houck, P, Dew, MA and Reynolds, CF (2003) Occurrence and course of suicidality during short-term treatment of late-life depression. Archives of General Psychiatry 60, 610–617.
Taylor, DJ, Walters, HM, Vittengl, JR, Krebaum, S and Jarrett, RB (2010) Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? Journal of Affective Disorders 123, 181–187.
Trivedi, MH, Rush, AJ, Wisniewski, SR, Nierenberg, AA, Warden, D, Ritz, L, Norquist, G, Howland, RH, Lebowitz, B, McGrath, PJ, Shores-Wilson, K, Biggs, MM, Balasubramani, GK, Fava, M and STAR*D Study Team (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28–40.
Trivedi, MH, Morris, DW, Wisniewski, SR, Nierenberg, AA, Gaynes, BN, Kurian, BT, Warden, D, Stegman, D, Shores-Wilson, K and Rush, AJ (2013) Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. The Canadian Journal of Psychiatry 58, 113–122.
Weitz, ES, Hollon, SD, Twisk, J, van Straten, A, Huibers, MJ, David, D, DeRubeis, RJ, Dimidjian, S, Dunlop, BW, Cristea, IA, Faramarzi, M, Hegerl, U, Jarrett, RB, Kheirkhah, F, Kennedy, SH, Mergl, R, Miranda, J, Mohr, DC, Rush, AJ, Segal, ZV, Siddique, J, Simons, AD, Vittengl, JR and Cuijpers, P (2015) Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual patient data meta-analysis. JAMA Psychiatry 72, 1102–1109.
Wightman, DS, Foster, VJ, Krishen, A, Richard, NE and Modell, JG (2010) Meta-analysis of suicidality in placebo-controlled clinical trials of adults taking bupropion. Primary Care Companion to The Journal of Clinical Psychiatry 12, pii: PCC.09m00894.
Wilkinson, ST, Ballard, ED, Bloch, MH, Mathew, SJ, Murrough, JW, Feder, A, Sos, P, Wang, G, Zarate, CA and Sanacora, G (2018) The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. American Journal of Psychiatry 175, 150–158.
Williams, JB and Kobak, KA (2008) Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). British Journal of Psychiatry 192, 52–58.
Yang, H, Chuzi, S, Sinicropi-Yao, L, Johnson, D, Chen, Y, Clain, A, Baer, L, McGrath, PJ, Stewart, JW, Fava, M and Papakostas, GI (2010) Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. European Archives of Psychiatry and Clinical Neuroscience 260, 145–150.